|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In PTEN-null GBM models, LOX inhibition markedly suppresses macrophage infiltration and tumor progression.
|
31185211 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lysyl oxidase (LOX) enzyme has attracted attention due to its involvement in tumor progression in various cancers.
|
31599475 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.
|
31320631 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The LOX family members function to cross-link collagen in the extracellular matrix (ECM) to promote cancer progression and metastasis.
|
29799025 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In the present study, we investigated the role of lysyl oxidase‑like 2 (LOXL2), the correlation between LOXL2 and epithelial to mesenchymal transition (EMT) and the effects of using β‑aminopropionitrile (BAPN) to inhibit LOXL2 with the aim of reducing tumor progression in hepatocellular carcinoma (HCC).
|
29620290 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lysyl oxidase (LOX) is another extracellular protein involved in collagen cross-linking and remodeling of extracellular matrix and has been correlated with tumor progression.
|
30583585 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The lysyl oxidase-like protein LOXL2 has been suggested to contribute to tumor progression and metastasis, but <i>in vivo</i> evidence has been lacking.
|
28720577 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Emerging evidence has implicated a pivotal role for lysyl oxidase (LOX) in cancer progression and metastasis.
|
28947950 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Accordingly, recent studies have supported a pivotal role for LOX in cancer progression and metastasis.
|
28495238 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumour progression.
|
28416796 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LOX in colorectal cancer synergizes with hypoxia-inducible factor-1 (HIF-1) to promote tumor progression.
|
27742687 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Our findings provide new evidence that LOX regulates SNAI2 expression and that SNAI2-mediated TIMP4 secretion plays a role in cancer progression.
|
27029493 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our work is the latest in an emerging body of work supporting the targeting of LOX and calls for greater efforts in developing therapeutics against this extracellular secreted factor in the prevention of cancer progression across multiple solid tumor types.
|
26732355 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lysyl oxidase-like 2 (LOXL2) is a member of the lysyl oxidase family, which plays an important role in extracellular matrix protein biosynthesis and tumor progression.
|
27063404 |
2016 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Recently, a number of studies have shown that LOX is overexpressed in most cancers and that it is involved in the regulation of tumor progression and metastasis.
|
28036074 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LOX promote tumour progression and metastasis, but it may also have tumour-inhibitory effects.
|
26804196 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The lysyl oxidase (LOX) family is comprised of five members, and some members have recently emerged as important regulators of tumor progression.
|
26329904 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate a differential regulation of LOX-expression and secretion in response to IR and hypoxia, and suggest that LOX may contribute towards an IR-induced migratory phenotype in sublethally-irradiated tumor cells and tumor progression.
|
25052686 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lysyl oxidase (LOX), a copper-dependent amine oxidase known to function both intracellularly and extracellularly, is implicated in promoting tumor progression and hypoxic metastasis in certain malignancies.
|
23140307 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lysyl oxidase family members have various roles in cancer progression.
|
22204712 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this review we explain in detail the role of lysyl oxidase in tumor progression and metastasis.
|
21107914 |
2011 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LOX-mediated effects on tumor progression were associated with SRC activation, and these effects were inhibited by dasatinib.
|
21282564 |
2011 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
However, positive correlation is lost in metastatic tumors, suggesting that LOX expression is independent of a hypoxic environment at later stages of tumor progression.
|
17685448 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taken together, the literature demonstrates the increasingly important role(s) that LOX may play in regulating tumor progression and the necessity to elucidate its myriad mechanisms of action in order to identify potentially novel therapeutics.
|
17471532 |
2007 |